BIOREGENX, INC. (BRGX) stock: key figures, P/E, revenue and dividend

Information Technology · United States

Price
0.00 USD
Market cap
95,971.00 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

BIOREGENX, INC. financials

Fiscal year2025
Revenue1.85 m USD
Gross profit1.50 m USD
Operating income-1.24 m USD
EBIT-1.24 m USD
Net income-1.54 m USD
Diluted EPS – continuing operations0.00 USD

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About BIOREGENX, INC.

BioRegenx, Inc. engages in the research, development, and commercialization of dietary supplements, medical devices, software, and contactless diagnostic technologies in the United States and internationally. The company offers DocSun AI engine, which integrates with a ballistocardiograph that detects an individual's heartbeat; TruScan.AI mobile app for additional health indications; VitalWellness app for DNA and epigenetics platform; and Endocalyx Pro, a dietary supplement targeting microvascular capillary health. It also provides MyBodyRx, a supplement; GlycoCheck software and medical devices; hydrogen water products and health and wellness devices, such as pulsed electro-magnetic field devices; StimaWELL and ReLounge electronic muscle stimulation therapy devices; and Findit.com, a social media content management platform. The company sells its products through a direct selling channel to health professionals and research organizations. BioRegenx, Inc. is headquartered in Chattanooga, Tennessee.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.